M&A Deal Summary

CSL Behring Acquires Vitaeris

On June 8, 2020, CSL Behring acquired life science company Vitaeris

Acquisition Highlights
  • This is CSL Behring’s 2nd transaction in the Life Science sector.
  • This is CSL Behring’s 1st transaction in Canada.
  • This is CSL Behring’s 1st transaction in British Columbia.

M&A Deal Summary
Date 2020-06-08
Target Vitaeris
Sector Life Science
Buyer(s) CSL Behring
Deal Type Add-on Acquisition

Target

Vitaeris

Vancouver, British Columbia, Canada
Vitaeris, Inc. is a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients. Vitaeris was founded in 2016 and is based in Vancouver, British Columbia.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

CSL Behring

King of Prussia, Pennsylvania, United States
Category Company
Founded 2000
Sector Life Science
DESCRIPTION

CSL Behring LLC is a global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. CSL Behring LLC was established in 2000 and is based in King of Prussia, Pennsylvania.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (British Columbia) 1 of 1
Country (Canada) 1 of 1
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-28 Calimmune

Tuscon, Arizona, United States

Calimmune, Inc. is a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy. Calimmune, Inc. was founded in 2000 and is based in Tuscon, Arizona.

Buy $91M
Mergr

Product

Company

Legal